Hypoxia modulates the activity of a series of clinically approved tyrosine kinase inhibitors
British Journal of Pharmacology2013Vol. 171(1), pp. 224–236
Citations Over Time
Maryam Ahmadi, Zeynab Ahmadihosseini, Simon J. Allison, Selina Begum, Kimberly L. Rockley, Maria Sadiq, S Chintamaneni, Ravi Lokwani, Nicola Hughes, Roger M. Phillips
Abstract
Hypoxia influences the activity of TKIs but in contrast to conventional cytotoxic drugs, preferential activity against hypoxic cells can occur. The search for hypoxia-targeted therapies has been long and fruitless and this study suggests that some clinically approved TKIs could preferentially target the hypoxic fraction of some tumour types.
Related Papers
- → Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia(2009)122 cited
- → Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma(2017)36 cited
- → Sorafenib regulating ERK signals pathway in gastric cancer cell(2014)2 cited
- → Dasatinib for the treatment of chronic myeloid leukemia(2011)4 cited
- SPOTLIGHT REVIEW Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia(2009)